



HUMANARZNEIMITTEL - EMA	2
<i>Allgemeines – General</i>	2
<i>Pharmakovigilanz – PRAC</i>	2
<i>Zulassung – Regulatory Affairs</i>	3
<i>Orphan Drugs und neuartige Therapierichtungen (ATMP)</i>	6
<i>Qualität – Quality</i>	7
<i>(Prä-) Klinische Forschung – Research and Development</i>	7
<i>Kinderarzneimittel – Paediatrics</i>	8
<i>Pflanzliche Arzneimittel – Herbal medicines</i>	9
EUROPEAN COMMISSION	10
EDQM	11
MEDIZINPRODUKTE	12
CMDH	13
HUMANARZNEIMITTEL - DEUTSCHLAND	14
HUMANARZNEIMITTEL - ÖSTERREICH	17
ARZNEIMITTEL - SCHWEIZ	18
	
FRAGEN AN DAS NETZWERK	19
VERANSTALTUNGEN / EVENTS – BEHÖRDEN UND ANDERE VERANSTALTER	20
DEUTSCHLAND	20
ÖSTERREICH	20
SCHWEIZ	20
EUROPA	20
<u>Urheberrechtshinweis:</u>	

Der MEGRA Newsletter und die darin enthaltenen Beiträge sind urheberrechtlich geschützt. Ohne die ausdrückliche Genehmigung der Urheber oder der Inhaber der Nutzungsrechte darf weder der MEGRA Newsletter noch Teile davon verbreitet, bearbeitet, öffentlich zugänglich, vorgetragen, in einem Abrufsystem gespeichert oder in ein solches eingeführt oder in einer beliebigen anderen Form (elektronisch, mechanisch, per Hyperlink, per Fotokopie, per Aufzeichnung oder auf anderem Wege) oder zu einem beliebigen anderen Zweck vervielfältigt oder übermittelt werden. Downloads und Kopien des Newsletters sind nur Mitgliedern der *Mittel Europäischen Gesellschaft für Regulatory Affairs e.V. (MEGRA)* und für den privaten, nicht kommerziellen Gebrauch gestattet. Durch das Herunterladen oder Kopieren von Inhalten werden keine Rechte bezüglich der Inhalte übertragen.

Humanarzneimittel - EMA

Allgemeines – General

Contact details of national competent authorities for requests to use a sticker to place the Unique Identifier on the outer/immediate packaging of centrally approved products (updated)

Published on: 18 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/contact-details-national-competent-authorities-requests-use-sticker-place-unique-identifier-outer/immediate-packaging-centrally-approved-products_en.pdf

Scientific publications (updated)

Published on: 21 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/news-events/publications/scientific-publications>

World Health Organization (WHO) (updated)

Published on: 21 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/partners-networks/international-activities/multilateral-coalitions-initiatives/world-health-organization-who>

What we do (updated)

Published on: 01 - March - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/about-us/what-we-do>

Regulation on EMA's extended mandate becomes applicable

Published on: 01 - March - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/news/regulation-emas-extended-mandate-becomes-applicable>

Pharmakovigilanz – PRAC

Referral: Nomegestrol and chlormadinone , nomegestrol, chlormadinone, Article 31 referrals, Under evaluation, 21/02/2022 (updated)

Published on: 21 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/medicines/human/referrals/nomegestrol-chlormadinone>

Referral: Terlipressin-containing medicinal products indicated in the treatment of hepatorenal syndrome , terlipressin, Article 31 referrals, Procedure started

Published on: 21 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/medicines/human/referrals/terlipressin-containing-medicinal-products-indicated-treatment-hepatorenal-syndrome>

Humanarzneimittel - EMA

Referral: Procaine benzylpenicillin , Article 82, Procedure started, 18/02/2022

Published on: 23 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/medicines/veterinary/referrals/procaine-benzylpenicillin>

Regulatory and procedural guideline: EU Individual Case Safety Report (ICSR) implementation guide business rules spreadsheets (updated)

Published on: 23 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/eu-individual-case-safety-report-icsr-implementation-guide-business-rules-spreadsheets_en.zip

Regulatory and procedural guideline: EudraVigilance - EVWEB user manual - Version 1.6 (updated)

Published on: 23 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/eudravigilance-evweb-user-manual-version-16_en.pdf

Hydroxyethyl-starch solutions for infusion recommended for suspension from the market

Published on: 25 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/news/hydroxyethyl-starch-solutions-infusion-recommended-suspension-market>

List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs) (updated)

Published on: 02 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/list-european-union-reference-dates-frequency-submission-periodic-safety-update-reports-psurs_en.xls

Zulassung – Regulatory Affairs

Regulatory and procedural guideline: Member states contact points for translations review (updated)

Published on: 18 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/member-states-contact-points-translations-review_en.pdf

Regulatory and procedural guideline: List of centrally authorised products requiring a notification of a change for update of annexes (updated)

Published on: 21 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/list-centrally-authorised-products-requiring-notification-change-update-annexes_en.pdf

Humanarzneimittel - EMA

Regulatory and procedural guideline: European Medicines Agency guidance for applicants seeking scientific advice and protocol assistance (updated)

Published on: 24 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/european-medicines-agency-guidance-applicants-seeking-scientific-advice-protocol-assistance_en.pdf

Regulatory and procedural guideline: Procedural advice – extended assessment time for initial marketing authorisation applications of 90 days

Published on: 25 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/procedural-advice-extended-assessment-time-initial-marketing-authorisation-applications-90-days_en.pdf

Regulatory and procedural guideline: Substances considered as not falling within the scope of Regulation (EC) No. 470/2009, with regard to residues of veterinary medicinal products in foodstuffs of animal origin (updated)

Published on: 25 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/substances-considered-not-falling-within-scope-regulation-ec-no-470/2009-regard-residues-veterinary-medicinal-products-foodstuffs-animal-origin_en.pdf

Regulatory and procedural guideline: Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans - in relation to implementing measures under Article 37(5) of Regulation (EU) 2019/6 on veterinary medicinal products

Published on: 01 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/regulatory-procedural-guideline/advice-designation-antimicrobials-groups-antimicrobials-reserved-treatment-certain-infections-humans/6-veterinary-medicinal-products_en.pdf

Union Product Database - FAQs - questions and answers for industry users (updated)

Published on: 18 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/union-product-database-faqs-questions-answers-industry-users_en.pdf

Agenda: Agenda - CHMP agenda of the 21-24 February 2022 meeting

Published on: 21 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-21-24-february-2022-meeting_en.pdf

Humanarzneimittel - EMA

Minutes: CHMP PROM minutes for the meeting on 17 January 2022

Published on: 23 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/minutes/chmp-prom-minutes-meeting-17-january-2022_en.pdf

Agenda: CHMP PROM agenda for the meeting on 17 January 2022

Published on: 23 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/agenda/chmp-prom-agenda-meeting-17-january-2022_en.pdf

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022

Published on: 25 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022>

Article 57 product data (updated)

Published on: 21 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/article-57-product-data_en.xlsx

European medicines regulatory network adopts EU common standard for electronic product information

Published on: 22 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/news/european-medicines-regulatory-network-adopts-eu-common-standard-electronic-product-information>

Product-information requirements (updated)

Published on: 22 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/product-information-requirements>

Agenda - Third European Medicines Agency and Association of the European Self-Medication Industry (AESGP) annual bilateral meeting

Published on: 23 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/agenda/agenda-third-european-medicines-agency-association-european-self-medication-industry-aesgp-annual_en.pdf

List of medicinal products under additional monitoring (updated)

Published on: 24 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/additional-monitoring/list-medicinal-products-under-additional-monitoring_en-0.pdf

Humanarzneimittel - EMA

European Medicines Agency's Data Protection Notice concerning the Multistakeholder Workshop on EMA extended mandate on 1 April 2022

Published on: 24 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/european-medicines-agency-data-protection-notice-concerning-multistakeholder-workshop-ema-extended_en.pdf

Presentation: Introducing DADI –The Digital Application Dataset Integration Network Project to replace electronic application forms

Published on: 24 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/presentation/presentation-introducing-dadi-digital-application-dataset-integration-network-project-replace_en.pdf

Interpretation of Article 18(7) of Regulation (EU) 2019/6 (updated)

Published on: 25 - February - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/interpretation-article-187-regulation-eu-2019-6>

List of products granted eligibility to PRIME (updated)

Published on: 02 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/report/list-products-granted-eligibility-prime_en-0.xlsx

Orphan Drugs und neuartige Therapierichtungen (ATMP)

Agenda: Agenda - COMP agenda of the 15-17 February 2022 meeting

Published on: 21 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/agenda/agenda-comp-agenda-15-17-february-2022-meeting_en.pdf

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 21-24 February 2022

Published on: 02 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-21-24-february-2022_en.pdf

PRIME: Analysis of the first 5 years' experience

Published on: 03 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/report/prime-analysis-first-5-years-experience_en.pdf und https://www.ema.europa.eu/documents/report/prime-5-years-experience_en.pdf

Humanarzneimittel - EMA

PRIME enables earlier availability of life-changing medicines

Published on: 03 - March - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/news/prime-enables-earlier-availability-life-changing-medicines>

Qualität – Quality

No news published

(Prä-) Klinische Forschung – Research and Development

CTIS newsflash - 18 February 2022

Published on: 23 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/newsletter/ctis-newsflash-18-february-2022_en.pdf

Principal documents taken into account for the preparation of procedures for GCP inspections requested by the CHMP (updated)

Published on: 18 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/principal-documents-taken-account-preparation-procedures-gcp-inspections-requested-chmp_en.pdf

Quick guide - Fill in the blanks exercise: Overview of CTIS workspaces and common system functionalities - CTIS Training Programme - Module 02

Published on: 01 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/quick-guide-fill-blanks-exercise-overview-ctis-workspaces-common-system-functionalities-ctis_en.pdf and

https://www.ema.europa.eu/documents/other/clinical-trials-information-system-ctis-common-features-ctis-training-programme-module-02_en.pdf

FAQs: Overview of CTIS workspaces and common system functionalities - CTIS Training Programme - Module 02 (updated)

Published on: 02 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/faqs-overview-ctis-workspaces-common-system-functionalities-ctis-training-programme-module-02_en.pdf

Presentation: Clinical Trials Information System (CTIS) bitesize talk: User access and role management

Published on: 01 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/presentation/presentation-clinical-trials-information-system-ctis-bitesize-talk-user-access-role-management_en.pdf

Humanarzneimittel - EMA

Newsletter: CTIS newsflash - 25 February 2022

Published on: 01 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/newsletter/ctis-newsflash-25-february-2022_en.pdf

Clinical Trials Information System (CTIS) - Technical requirements for optimal use

Published on: 03 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/other/clinical-trials-information-system-ctis-technical-requirements-optimal-use_en.pdf

Template or form: Innovation Task Force (ITF) briefing meeting request form (updated)

Published on: 03- March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/template-form/innovation-task-force-itf-briefing-meeting-request-form_en.docx

Kinderarzneimittel – Paediatrics

Minutes: PDCO monthly report of opinions on paediatric investigation plans and other activities 12-15 October 2021

Published on: 18 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/minutes/pdco-monthly-report-opinions-paediatric-investigation-plans-other-activities-12-15-october-2021_en.pdf

Work programme: PDCO work plan 2022

Published on: 21 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/work-programme/pdco-work-plan-2021_en.pdf

Agenda - PDCO agenda of the 22-25 February 2022 meeting

Published on: 25 - February - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/agenda/agenda-pdco-agenda-22-25-february-2022-meeting_en.pdf

Minutes - PDCO minutes of the 7-10 September 2021 meeting

Published on: 02 - March - 2022

For more information, please refer to:

https://www.ema.europa.eu/documents/minutes/minutes-pdco-minutes-7-10-september-2021-meeting_en.pdf

Humanarzneimittel - EMA

Pflanzliche Arzneimittel – Herbal medicines

No news published

Eudralex Volume 4 - EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use

Published on: 21 - February - 2022

For more information, please refer to:

https://ec.europa.eu/health/latest-updates/eudralex-volume-4-eu-guidelines-good-manufacturing-practice-medicinal-products-human-and-veterinary-2022-02-21_en

Minutes - 1st drafting group meeting on managing AMR across the health system (28 January 2022)

Published on: 21 - February - 2022

For more information, please refer to:

https://ec.europa.eu/health/latest-updates/minutes-1st-drafting-group-meeting-managing-amr-across-health-system-28-january-2022-2022-02-21_en

Factsheet - EU Action on Rare Diseases

Published on: 25 - February - 2022

For more information, please refer to:

https://ec.europa.eu/health/latest-updates/factsheet-eu-action-rare-diseases-2022-02-25_en

EDQM remote inspections: from pilot phase to a permanent element of EDQM's inspection scheme!

Published on: 23 - February - 2022

For more information, please refer to:

<https://www.edqm.eu/en/news/edqm-remote-inspections-pilot-phase-permanent-element-edqms-inspection-scheme>

PDG 2021 autumn meeting held by videoconference

Published on: 01 - March - 2022

For more information, please refer to:

<https://www.edqm.eu/en/news/pdg-2021-autumn-meeting-held-videoconference>

Update of application forms for Certificate of Suitability applications

Published on: 02 - March - 2022

For more information, please refer to:

<https://www.edqm.eu/en/news/update-application-forms-certificate-suitability-applications>

Suspension of shipments

"Due to the recent events in Ukraine, all carriers have suspended their activities in Belarus, Moldova, Russia and Ukraine until further notice. Therefore, the EDQM can no longer proceed with any shipments for Reference Standards, Publications or PTS to these countries."

Published on: 02 - March - 2022

For more information, please refer to:

<https://www.edqm.eu/en/news/suspension-shipments>

Medizinprodukte

No news published

The 106th Heads of Medicines Agencies Meeting 23 - 24 November 2021 Highlights of the Meeting

Published on: 21 - February - 2022

For more information, please refer to:

https://www.hma.eu/fileadmin/dateien/HMA_joint/03-Stakeholders_Info/Stakeholders_106th_HMA_Ljubljana_November_2021.pdf

HMA Procedures and Governance - For the Permanent Secretariat Support to the HMA Management Group (updated March 2022)

Published on: 03 - March - 2022

For more information, please refer to:

<https://www.hma.eu/about-hma/structure.html#c3940>

Summary of CMDh Activities 2021

Published on: 03 - March - 2022

For more information, please refer to:

<https://www.hma.eu/human-medicines/cmdh/about-cmdh/cmdh-reports.html#c6973>

Humanarzneimittel - Deutschland

Organigramm des BfArM - Stand 18.02.2022

Veröffentlicht am: 18 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/SharedDocs/Downloads/DE/BfArM/Org/bfarm_organigramm.html?nn=986770

Bearbeitungsstatistiken

Veröffentlicht am: 21 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Aktuelles/Statistiken/AM_statistik/statistik-bearbeitung.html

Statistik "Besondere Therapierichtungen und Traditionelle Arzneimittel"

„Die Statistiken zu den verkehrsfähigen Arzneimitteln der Besonderen Therapierichtungen (Phytopharmaka, Homöopathika, Anthroposophika) sowie traditioneller Arzneimittel, die erfolgreich ein (Nach-)Zulassungs- oder (Nach-)Registrierungsverfahren abgeschlossen haben, wurden aktualisiert.“

Veröffentlicht am: 25 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Aktuelles/Statistiken/AM_statistik/Besondere_Therapierichtungen_statistik/statistik-bescheidzahlen.html

Arzneimittelzulassungen unter Verwendung von Studien der Firma GVK Biosciences in Indien: Ruhen der Zulassungen

„Wirkstoff: Verschiedene“

Veröffentlicht am: 22 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RV_STP/q-l/gvk.html

Vorläufige Tagesordnung der 90. Routinesitzung am 15. März 2022

„Die 90. Routinesitzung nach § 63 AMG wird am 15. März 2022 ab 10:00 Uhr als Videokonferenz stattfinden.“

Veröffentlicht am: 23 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Ausschuesse-und-Gremien/Routinesitzung/Protokolle/90Sitzung/tagesordnung_90.html

Schreiben BMG vom 22.02.2022 - Versorgungsmangel tamoxifenhaltiger Arzneimittel

Veröffentlicht am: 23 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/amInformationen/Lieferengpaesse/schreiben_bmg_tamoxifenhaltige_am_20220222.html?nn=986770

Bescheid vom 22.02.2022 - Anordnung gemäß § 52b Absatz 3d AMG für tamoxifenhaltige Arzneimittel

Veröffentlicht am: 23 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/amInformationen/Lieferengpaesse/bescheid_52b_3d_tamoxifenhaltige_am.html?nn=986770

Humanarzneimittel - Deutschland

Vortragsfolien: Praktische Planung und Durchführung von klinischen Studien II

Veröffentlicht am: 23 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/SharedDocs/Downloads/DE/Service/Termine-und-Veranstaltungen/ringvorlesungen/2021_Winter/Praktische_Planung_Durchfuehrung_Coenen.pdf?blob=publicationFile

Formular - Meldung von Vorkommnissen durch sonstige Inverkehrbringer sowie Betreiber und Anwender nach § 3 Abs. 2 bis 4 der Medizinprodukte Sicherheitsplanverordnung

Veröffentlicht am: 24 - Februar - 2022

Weitere Informationen finden Sie unter:

<https://www.bfarm.de/SharedDocs/Formulare/DE/Medizinprodukte/caVorkommnismeldungen-sonstige-Inverkehrbringer-PDF.html?nn=986770>

Antrag auf Erlaubnis zur Teilnahme am Betäubungsmittelverkehr nach § 3 Betäubungsmittelgesetz (BtMG) für außeruniversitäre wissenschaftliche Einrichtungen und Behörden

Veröffentlicht am: 28 - Februar - 2022

Weitere Informationen finden Sie unter:

<https://www.bfarm.de/SharedDocs/Formulare/DE/Bundesopiumstelle/BtM/WissBehoerdenAntrag.html?nn=986770>

Erlaubnis und Registrierung

„Jeder, der Grundstoffe der Kategorie 1 besitzt, in den Verkehr bringt, einführt, ausführt bzw. mit ihnen Vermittlungs- oder Streckengeschäfte betreibt, benötigt dafür eine Erlaubnis nach Artikel 3 Abs. 2 der Verordnung (EG) Nr. 273/2004 bzw. Artikel 6 Abs. 1 der Verordnung (EG) Nr. 111/2005.“

Veröffentlicht am: 28 - Februar - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Bundesopiumstelle/Grundstoffe/Erlaubnis/_artikel.html?nn=986770

PEI-C Rebuild – Elektronische Zustellung der Chargenfreigabedokumente für weitere Produktgruppen

Veröffentlicht am: 28 - Februar - 2022

Weitere Informationen finden Sie unter:

<https://www.pei.de/SharedDocs/Downloads/DE/newsroom/mitteilungen/220228-elektronische-zustellung-chargenfreigabedokumente-2.pdf?blob=publicationFile&v=2>

Expertengruppen Off-Label

„Stellenausschreibung externe Sachverständige - Es liegen neue Arbeitsaufträge zur Vergabe vor.“

Veröffentlicht am: 03 - März - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Arzneimittel/Zulassung/Zulassungsrelevante-Themen/Expertengruppen-Off-Label/_artikel.html

CHMP Ausschuss für Humanarzneimittel

Veröffentlicht am: 03 - März - 2022

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Das-BfArM/Aufgaben/EU-und-Internationales/CHMP-Ausschuss/_artikel.html?nn=986770

Humanarzneimittel - Deutschland

Für den Fortschritt biomedizinischer Arzneimittel: Paul-Ehrlich-Institut im Gespräch mit dem Bundesverband der Pharmazeutischen Industrie (BPI)

Veröffentlicht am: 03 - März - 2022

Weitere Informationen finden Sie unter:

<https://www.pei.de/DE/newsroom/hp-meldungen/2022/220303-pei-bpi-meeting.html;jsessionid=ECA153456C0DB2FC5A76276DD9977E38.intranet221?nn=170852>

Allergenimmuntherapie – viele Studien, wenige Zulassungen – woran liegt es?

Veröffentlicht am: 03 - März - 2022

Weitere Informationen finden Sie unter:

<https://www.pei.de/DE/newsroom/pm/jahr/2022/05-allergenimmuntherapie-viele-studien-viele-zulassungen-woran-liegt-es.html;jsessionid=F72E4D98A9005B4A08B1474A047FBEFD.intranet231?nn=172068>

Humanarzneimittel - Österreich

PRAC signal recommendation - Pregabalin

Veröffentlicht am: 22 - Februar - 2021

Weitere Informationen finden Sie unter:

https://www.basq.gv.at/fileadmin/redakteure/07_Unternehmen/PV-Mustertexte/220222_Mustertext_Pregabalin.pdf

PSUR-outcome - Azithromycin

Veröffentlicht am: 22 - Februar - 2021

Weitere Informationen finden Sie unter:

https://www.basq.gv.at/fileadmin/redakteure/07_Unternehmen/PV-Mustertexte/220222_Mustertext_Azithromycin.pdf

PSUR-outcome - Tacrolimus (systemische Formulierungen)

Veröffentlicht am: 25 - Februar - 2021

Weitere Informationen finden Sie unter:

<https://ec.europa.eu/health/documents/community-register/html/ho27654.htm>

96. Anlage der Geschäftsordnung des BASG

Veröffentlicht am: 23 - Februar - 2021

Weitere Informationen finden Sie unter:

<https://www.basq.gv.at/ueber-uns/basq-veroeffentlichungen/geschaeftsordnung#c3430>

Vision, Werte und Strategie NEU

„Wir wollen eine der führenden Arzneimittelagenturen Europas sein.

Wir sind die zuständige nationale Aufsichtsbehörde für Arzneimittel, Medizinprodukte, Blut und Gewebe und Partner der zuständigen europäischen Aufsichtsbehörden und Agenturen.“

Veröffentlicht am: 03 - März - 2021

Weitere Informationen finden Sie unter:

<https://www.basq.gv.at/ueber-uns/vision-werte-und-strategie>

Arzneimittel - Schweiz

Zulassungen von Humanarzneimitteln mit neuem Wirkstoff und Indikationserweiterungen 2021

Veröffentlicht am: 25 - Februar - 2022

Weitere Informationen finden Sie unter:

<https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/informationen/zl-ham-neue-ws-und-indikationserweiterungen-2021.html>

Anpassung der VL Fachinformation TAM / Anpassung der VL Packungsbeilage TAM

„Die angepassten Vorlagen sind ab 1. März 2022 gültig“

Veröffentlicht am: 01 - März - 2022

Weitere Informationen finden Sie unter:

<https://www.swissmedic.ch/swissmedic/de/home/tierarzneimittel/informationen/anpassungen-vorlagen-fi-pi-tam.html>

Medizinprodukte Datenbank

„Beachten Sie bitte die Informationen zur Medizinprodukte Datenbank“

Veröffentlicht am: 01 - März - 2022

Weitere Informationen finden Sie unter:

<https://www.swissmedic.ch/swissmedic/de/home/medizinprodukte/medizinprodukte-datenbank.html>

Update Merkblatt - Einmalige Identifikationsnummer (CHRN – Swiss Single Registration Number)

Veröffentlicht am: 03 - März - 2022

Weitere Informationen finden Sie unter:

<https://www.swissmedic.ch/swissmedic/de/home/medizinprodukte/marktzugang/registriernummer-chrn.html>

Aktualisierte Vorgabedokumente – Februar und März

„-ZL000_00_022d_WL Wegleitung Zulassung nach Art. 14 Abs. 1 Bst. abis-quater HMG HMGV4 (28.02.2022)

-ZL000_00_023d_WL Wegleitung Pädiatrisches Prüfkonzept HMGV4 (25.02.2022)

-BW630_10_003d_MB Einmalige Identifikationsnummer - CHRN (03.03.2022)

-BW690_00_002d_WL Exportzertifikate (03.03.2022)“

Veröffentlicht am: 03 - März - 2022

Weitere Informationen finden Sie unter:

https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated_documents/feb-2022.html und

https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated_documents/maerz-2022.html



Fragen an das Netzwerk

Falls Sie eine Frage haben, die Sie gerne in unserem Netzwerk diskutieren würden, senden Sie uns einfach eine E-Mail an info-as@megra.org zur anonymen Publikation im nächsten Newsletter.*

*Bei der Beantwortung der Fragen handelt es sich um eine Zusammenfassung von persönlichen Meinungen und Erfahrungswerten der MEGRA Mitglieder mit keinem Anspruch auf Rechtssicherheit. Wir empfehlen zur Absicherung die Konsultation entsprechender zugrunde liegender Regularien.

Veranstaltungen / Events – Behörden und andere Veranstalter

Deutschland

How to DiGA: Webinare mit Anforderungen, Erfahrungen und Tipps aus der DiGA-Antragsbewertung

Where: Virtual meeting

Date:

22 - März – 2022, 09:30 bis 12:30 Uhr, „Datensicherheit bei DiGA“

04 - Mai – 2022, 09:30 bis 12:30 Uhr, „Datensicherheit bei DiGA“

23 - September – 2022, 09:30 bis 12:30 Uhr, „Interoperabilität bei DiGA“

For more information, please refer to:

<https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/DiGA/Webinare/artikel.html>

BfArM im Dialog „Anwenderforum SNOMED CT“

Where: Virtual meeting

Date: 12- Mai – 2022, 10.00 – 14.00 Uhr

For more information, please refer to:

https://www.bfarm.de/DE/Aktuelles/Veranstaltungen/Termine/snomed_anwenderforum_2022-05-12.html

Österreich

AGES Online-Course "R for Data Science – Basic" (2 days)

Where: Virtual meeting

Date: 06 to 07 - April – 2022, 09:00 bis 17:00 Uhr

For more information, please refer to:

<https://www.ages.at/ages/veranstaltungen/veranstaltungskalender/detail/ages-online-course-r-for-data-science-basic-2-days>

Schweiz

Keine Veranstaltungen veröffentlicht

Europa

HPP webinar - The 'State of Health in the EU' in Slovakia (08 March 2022, 09:00 – 10:00 CET)

Where: Online

Date: 08 - March - 2022, 09:00 - 10:00 Amsterdam time (CEST)

For more information, please refer to:

https://ec.europa.eu/health/latest-updates/hpp-webinar-state-health-eu-slovakia-08-march-2022-0900-1000-cet-2022-03-01_en

Veranstaltungen / Events – Behörden und andere Veranstalter

Introduction to Organisation Management Service (OMS) and Referentials Management Service (RMS) services and activities: Industry webinar

Where: Online

Date: 10 - March - 2022, 10:00 - 12:00 and 14:00 - 16:00 Amsterdam time (CEST)

For more information, please refer to:

<https://www.ema.europa.eu/en/events/introduction-organisation-management-service-oms-referentials-management-service-rms-services-0>

System demo: digital application dataset integration (DADI) and Product Management Service (PMS)

Where: Virtual meeting

Date: 15 - March – 2022, 09:00 - 11:00 Amsterdam time (CET)

For more information, please refer to:

<https://www.ema.europa.eu/en/events/system-demo-digital-application-dataset-integration-dadi-product-management-service-pms>

HPP Webinar - Addressing climate change impacts on health through national policies

Where: Virtual meeting

Date: 16 - March – 2022, 10:00 - 11:15 Amsterdam time (CET)

For more information, please refer to:

https://ec.europa.eu/health/latest-updates/hpp-webinar-addressing-climate-change-impacts-health-through-national-policies-16-march-2022-1000-2022-02-18_en

Webinar on requesting access to and using EMA's substance, product, organisation and referential (SPOR) application programming interface (API)

Where: Online

Date: 18 - March - 2022, 14:00 - 16:00 Amsterdam time (CEST)

For more information, please refer to:

<https://www.ema.europa.eu/en/events/webinar-requesting-access-using-emas-substance-product-organisation-referential-spor-application>

Clinical Trials Information System (CTIS) bitesize talk: Initial clinical trial application

Where: Online

Date: 23 - March - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-bitesize-talk-initial-clinical-trial-application>

HPP Webinar - Fighting access to health inequalities by improving health worker retention and task shifting policies (29 March 2022, 14.30 - 16.30 pm CET)

Where: Online

Date: 29 - March – 2022, 14:30 - 16:30 Amsterdam time (CEST)

For more information, please refer to:

https://ec.europa.eu/health/latest-updates/hpp-webinar-fighting-access-health-inequalities-improving-health-worker-retention-and-task-shifting-2022-02-18_en

Veranstaltungen / Events – Behörden und andere Veranstalter

How to communicate efficiently with the EDQM on CEP applications

Where: Virtual meeting

Date: 29 - March – 2022, 10 a.m. to 11:15 a.m. (CEST)

For more information, please refer to:

<https://www.edqm.eu/en/events/how-communicate-efficiently-edqm-cep-applications>

Multistakeholder workshop on EMA's extended mandate

Where: Online

Date: 01 - April - 2022, 09:00 a.m. - 16:15 p.m. Amsterdam time (CET)

For more information, please refer to:

<https://www.ema.europa.eu/en/events/multistakeholder-workshop-emas-extended-mandate>

Getting the big picture: what has changed in the Ph. Eur. General Notices

Where: Online

Date: 07 - April - 2022, 2 p.m. to 3:15 p.m. (CEST)

For more information, please refer to:

<https://www.edqm.eu/en/events/getting-big-picture-what-has-changed-ph-eur-general-notices>

Clinical Trials Information System (CTIS) bitesize talk: Modifications

Where: Virtual meeting

Date: 28 - April – 2022, 14:00 - 15:00 Amsterdam time (CET)

For more information, please refer to:

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-bitesize-talk-modifications>

CTIS sponsor user training programme - six separate courses

Where: Online

Dates:

05 - 08 April 2022, 14:00 - 18:30 (CEST)

10 - 13 May 2022, 09:00 - 13:30 (CEST)

20 - 23 June 2022, 14:00 - 18:30 (CEST)

For more information, please refer to:

https://www.ema.europa.eu/documents/agenda/programme-clinical-trials-information-system-ctis-sponsor-end-user-training-programme-2022_en.pdf

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: Hands-on training course on using the EudraVigilance system

Where: Online meeting

Dates:

14 to 18 - March - 2022

04 to 08 - April - 2022

18 to 20 - May - 2022

13 to 17 - June - 2022

04 to 08 - July - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-training-support>

Veranstaltungen / Events – Behörden und andere Veranstalter

Virtual live hands-on training course for Clinical Trials Sponsors using EudraVigilance system

Where: Virtual meeting

Date: 04 to 06 - May - 2022

For more information, please refer to:

<https://www.ema.europa.eu/en/events/virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-0>

SAVE THE DATE! Conference celebrating the publication of the 11th Edition of the European Pharmacopoeia

Where: Virtual meeting

Date: 19 to 20 - September - 2022

For more information, please refer to:

<https://www.edqm.eu/en/news/save-date-conference-celebrating-publication-11th-edition-european-pharmacopoeia-19-21>